[
  {
    "ts": "2026-01-15T15:56:27+00:00",
    "headline": "JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death",
    "summary": "Intellia Therapeutics CEO John Leonard explained the circumstances of the patient death at the JP Morgan Healthcare Conference 2026.",
    "url": "https://www.clinicaltrialsarena.com/news/jpm26-intellia-therapeutics-hopeful-on-crispr-safety-despite-patient-death/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "398236db-5e88-3148-9b42-4245c07e74b3",
      "content": {
        "id": "398236db-5e88-3148-9b42-4245c07e74b3",
        "contentType": "STORY",
        "title": "JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death",
        "description": "",
        "summary": "Intellia Therapeutics CEO John Leonard explained the circumstances of the patient death at the JP Morgan Healthcare Conference 2026.",
        "pubDate": "2026-01-15T15:56:27Z",
        "displayTime": "2026-01-15T15:56:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/clinical_trials_arena_396/6195bd9f5366bb54ed9c3eb56e72584a",
          "originalWidth": 1000,
          "originalHeight": 750,
          "caption": "Intellia Therapeutics announced the patient death in November 2025. Image credit: Piotr Swat / Shutterstock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GQsdacVLIOWDx0lRPRsz0A--~B/aD03NTA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/6195bd9f5366bb54ed9c3eb56e72584a.cf.webp",
              "width": 1000,
              "height": 750,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iBvibXD1S0_0wb.x5FsDww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/clinical_trials_arena_396/6195bd9f5366bb54ed9c3eb56e72584a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/news/jpm26-intellia-therapeutics-hopeful-on-crispr-safety-despite-patient-death/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpm26-intellia-therapeutics-hopeful-crispr-155627347.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NTLA"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-15T19:33:12+00:00",
    "headline": "Genmab A/S (GMAB): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Genmab A/S on Gabriel Koh’s Substack. In this article, we will summarize the bulls’ thesis on GMAB. Genmab A/S’s share was trading at $33.87 as of January 13th. GMAB’s trailing and forward P/E were 14.83 and 12.58, respectively according to Yahoo Finance. Genmab is a leading biotechnology company focused […]",
    "url": "https://finance.yahoo.com/news/genmab-gmab-bull-case-theory-193312327.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "84488910-a477-3f82-8d6d-dc60b0b157aa",
      "content": {
        "id": "84488910-a477-3f82-8d6d-dc60b0b157aa",
        "contentType": "STORY",
        "title": "Genmab A/S (GMAB): A Bull Case Theory",
        "description": "",
        "summary": "We came across a bullish thesis on Genmab A/S on Gabriel Koh’s Substack. In this article, we will summarize the bulls’ thesis on GMAB. Genmab A/S’s share was trading at $33.87 as of January 13th. GMAB’s trailing and forward P/E were 14.83 and 12.58, respectively according to Yahoo Finance. Genmab is a leading biotechnology company focused […]",
        "pubDate": "2026-01-15T19:33:12Z",
        "displayTime": "2026-01-15T19:33:12Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/704b447d7d315c28926e416e7861f6b2",
          "originalWidth": 768,
          "originalHeight": 512,
          "caption": "Cidara (CDTX) Climbs 105% on $9.2-Billion Merger with Merck",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/S17jy7HkRSQ40DuUolziuQ--~B/aD01MTI7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/704b447d7d315c28926e416e7861f6b2.cf.webp",
              "width": 768,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BsjuUy03Rh5aTLM5BuzUug--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/704b447d7d315c28926e416e7861f6b2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/genmab-gmab-bull-case-theory-193312327.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/genmab-gmab-bull-case-theory-193312327.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GMAB"
            },
            {
              "symbol": "GNMSF"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]